Page 17 - Noble-Virtual-Healthcare-2024

CervoMed Inc.

SELECTED FINANCIAL ITEMS CRVO

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA 1.41 1.53 2.49 5.42
Gross Profit (0.34) (0.43) (0.23) (0.32) (1.32)
Gross Margin NM -30% -15% -13% -24%
EBIT (0.94) (2.06) (2.68) (1.68) (7.36)
EBIT Margin NM -147% -175% -67% -136%
Net Income to Common Shareholders (1.53) (1.17) 2.15 (2.36) (2.91)
Net Margin NM -83% 141% -95% -54%

Balance Sheet Key Items
Total Assets 4.16 3.31 12.04 9.97 9.97
Cash & Short Term Investments 4.09 2.61 10.42 7.79 7.79
% of Assets 98% 79% 87% 78% 78%
Current Assets -Total 4.16 3.31 11.84 9.96 9.96
% of Assets 100% 100% 98% 100% 100%
Total Liabilities 13.16 13.40 2.46 2.60 2.60
% of Assets 316% 406% 20% 26% 26%
Current Liabilities - Total 13.16 13.40 2.46 2.60 2.60
% of Assets 316% 406% 20% 26% 26%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (9.00) (10.10) 9.57 7.38 7.38
% of Assets -216% -306% 80% 74% 74%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (0.69) (1.48) NA (2.54) (4.71)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing NA NA NA (0.09) (0.09)

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference